CL vs UL: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: UL is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CL and UL share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CL and UL exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Colgate-Palmolive is a global consumer-staples company that makes everyday household and personal-care products. It is a worldwide leader in oral care, where its Colgate-branded toothpaste, toothbrushes, and mouthwash hold a leading global share, and it also sells personal care (soaps, body wash, deodorants under brands like Palmolive, Softsoap, Irish Spring, and Sanex), home care (dish and surface cleaners such as Palmolive and Ajax), and pet nutrition through its Hill's Pet Nutrition business (Science Diet and Prescription Diet). Colgate makes money by selling these branded, frequently repurchased products at scale across more than 200 countries and territories, with a particularly large presence in emerging markets. Its competitive advantages come from powerful brands, vast distribution, and pricing power on staple goods. Headquartered in New York City, Colgate is a defensive, dividend-paying company whose products people buy regardless of the economic cycle.

Full CL guide

Unilever PLC is one of the world's largest consumer-goods companies, and UL is its NYSE-listed ADR (the London line trades as ULVR, with a further listing in Amsterdam). After the late-2025 demerger of its ice cream arm, Unilever is organized around four business groups: Beauty & Wellbeing (Dove, Vaseline, and premium and wellness brands), Personal Care (deodorants, skin cleansing, and oral care such as Rexona and Lifebuoy), Home Care (laundry and cleaning brands like Persil and Cif), and Foods, also called Nutrition (Knorr, Hellmann's, and cooking products). A large share of turnover now comes from a concentrated set of roughly 30 Power Brands, which the company reports have been growing faster than the overall portfolio. Because it sells low-cost, repeat-purchase essentials, Unilever tends to hold up better than cyclical businesses in downturns, though it is exposed to input-cost inflation, currency swings, and slower volume growth in developed markets.

Full UL guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CL drivers: Oral-care leadership and emerging markets; Hill's Pet Nutrition growth.
• UL drivers: Power Brands and premiumization; Growth Action Plan and cost discipline.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Colgate's growth is structurally slow: it competes in mature, saturated staples categories where volume gains are hard to come by and much of recent revenue growth has come from price increases that may not persist. For UL, the main risk is that a slow-growth staples business trades on the credibility of its turnaround: if the Growth Action Plan does not lift volumes and margins as hoped, the stock can languish.

Pick CL if you believe its drivers more; UL if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CL and UL guides.

CL. Colgate trades at a premium consumer-staples multiple that reflects its defensive, recession-resistant cash flows, leading oral-care brands, the growth of Hill's, and a multi-decade dividend-raising record. The valuation premium is the market paying for stability and pricing power, balanced against the reality of slow underlying volume growth in mature categories.

UL. Figures are qualitative and tied to the asOf date; verify live numbers before acting. Unilever is valued as a stable, cash-generative consumer staple rather than a fast grower, so its multiple hinges on whether the Growth Action Plan can lift volume growth and margins. Because it is an ADR of a euro-reporting company, currency moves affect the dollar figures US investors see, including the dividend, independent of how the underlying business performs.

Headline figures (approximate, early 2026): CL shows revenue (ttm) ~$20 billion, operating margin ~20-21%, net income (ttm) ~$2.7 billion, dividend yield ~2-2.5% (Dividend King); UL shows business mix Four business groups after the ice cream demerger: Beauty & Wellbeing, Personal Care, Home Care, and Foods (Nutrition); verify live figures before acting, revenue scale Tens of billions of euros in annual turnover (reported in euros; UL is a dollar-denominated ADR), spread across roughly 190 countries; verify live figures before acting, underlying sales growth Mid-single-digit percentage in recent periods, led by Power Brands and beauty/personal care; verify the latest quarter before acting, dividend Pays a quarterly dividend and is widely held as a defensive income stock; treat any specific yield as a live figure to confirm before acting.

CL and UL are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CL and UL exposure against your real portfolio. It is not an investment adviser.